04:36 PM EST, 12/22/2025 (MT Newswires) -- Neurocrine Biosciences ( NBIX ) said Monday its phase 3 trial assessing the efficacy, safety, and tolerability of valbenazine in pediatric and adult participants with dyskinetic cerebral palsy did not meet primary or key secondary endpoints.

The primary goal of the trial was to evaluate improvement in chorea, which is a type of involuntary movement, in people with dyskinetic cerebral palsy, the company said.

Neurocrine shares were down 3.4% in after-hours activity.